Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,209.20
(
1.69%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
96.72
(
1.80%
)
Bitcoin
78,605.02
(
2.98%
)
News Focus
News Focus
Post# of 517493
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Bourbon_on_my_cornflakes

Send PM Follow Ignore
Followers 60
Posts 11377
Boards Moderated 0
Alias Born 01/31/2008

Bourbon_on_my_cornflakes

Re: RedShoulder post# 374339

Wednesday, 09/21/2022 10:43:34 AM

Wednesday, September 21, 2022 10:43:34 AM

Post# of 517493
One Obstacle: 92% of the high dose improved, no Parkinson drug has ever achieved that, not even close. I see no obstacles as A2-73 Blarcamesine is approved for both PD and PDD.

One obstacle. Glacial management's inability to get a p3 trial even STARTED after more than one year. WhereTF is it already?

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News